Skip to main content
null
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Brief Report
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Genetic Disorders
    • Hematology
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Nephrologic/Hepatologic Conditions
    • Neurological Disorders
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Perspective
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:32151/feed
Neurological Disorders
Vol. 1, Issue 1, 2013May 24, 2013 EDT

The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication

Christian Frois, Thomas O’Connell, Jacqueline Pesa, John Fastenau,
prior authorizationaccessformularypreferred drug list (pdl)medicaidschizophreniaantipsychotic
Copyright Logoccby-4.0 • https://doi.org/10.36469/9853
Photo by freestocks.org on Unsplash
JHEOR
1.
Frois C, O’Connell T, Pesa J, Fastenau J. The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication. JHEOR. 2013;1(1):54-61. doi:10.36469/​9853
Save article as...▾

View more stats

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Powered by Scholastica, the modern academic journal management system